Amicomed by Newel Health obtains EU MDR certification as a digital medical device for hypertension management
BASEL, Switzerland and MILAN, June 9, 2025 /PRNewswire/ -- Newel Health, a European HealthTech company specialized in certified digital medical devices, announced today that Amicomed, its solution for hypertension management, has received CE certification as a Class IIa medical device under the European Medical Device Regulation (MDR 2017/745). This milestone positions Amicomed among the leading candidate digital therapies poised to reshape hypertension management in Europe.
Amicomed supports individuals in daily blood pressure self-management by offering personalized feedback based on real-world data and helping users between clinical visits. It captures structured blood pressure data and translates it into clinically meaningful insights for users and healthcare professionals. Key features include medication reminders to improve adherence and personalized lifestyle and dietary recommendations based on the user's clinical profile.
In addition to its direct-to-consumer application, Amicomed can be deployed as a digital companion to antihypertensive therapies. It supports medication adherence and generates longitudinal behavioral insights. The solution has also been validated in population health programs for cardiovascular risk monitoring and chronic care optimization, as well as in digital insurance models focused on prevention and risk management. These use cases create pathways for adoption across pharmaceutical, insurance, and institutional ecosystems.
"We designed Amicomed to offer a digital therapy that fits into people's everyday lives, supporting them, day by day, in managing hypertension," said Ervin Ukaj, CEO of Newel Health. "The MDR certification confirms the strength of our platform and the reliability of our regulatory approach, enabling us to bring Amicomed to millions of individuals across Europe and to pursue scalable growth in partnership with public and private healthcare stakeholders."
Certified. Scalable. Integration-ready.
Compatible with Apple Health, Google Fit, and major Bluetooth-enabled blood pressure monitors, Amicomed also accepts manual data entry, ensuring usability without connected devices. It provides users with weekly reports, personalized notifications, and structured summaries, while clinicians can monitor progress between visits.
"Amicomed transformed available cardiovascular knowledge into a robust, intuitive digital solution designed for large-scale adoption," commented Professor Domenico Cianflone, member of the Scientific Advisory Board of Newel Health.
Amicomed will be distributed through a multi-channel strategy that includes direct-to-consumer, health insurance partners, digital pharmacies, corporate wellness programs, and public healthcare systems. Strategic discussions and pilot programs are currently underway across several European countries.
Powered by H.Core: AI and personalization at the center
Amicomed is built on H.Core, Newel Health's proprietary platform that integrates clinical logic, behavioral science, and real-world data to deliver personalized digital therapeutic pathways. H.Core uses predictive models powered by artificial intelligence to improve behavioral segmentation, sustain engagement, and adapt interventions to the individual profile. The platform ensures clinical consistency, scalability, and alignment with international standards for safety, performance, and software quality.
About Newel Health
Newel Health is a European HealthTech company developing certified digital medical devices that combine clinical science, behavioral psychology, and intelligent technology. With teams in Milan, Basel, Salerno and Tallinn, the company creates software-based therapeutics that address chronic diseases where user behavior and real-world data are central to clinical outcomes.
At Newel, user experience is part of the clinical model. Every solution is designed to be intuitive, engaging, and scalable. Through its proprietary platform H.Core, Newel enables continuous product optimization informed by behavioral analytics and longitudinal health signals.
Newel operates a full-stack infrastructure for the development, certification, and
commercialization of software as a medical device across global markets, including the European Union, the United States, and China. The company works with pharmaceutical leaders, health insurers, and public health systems to co-develop and scale regulated therapeutics that are clinically validated, commercially viable, and globally deployable.
Newel's portfolio includes certified therapeutics for hypertension (Amicomed) and chronic pain (Rohkea), with additional programs in Parkinson's disease, metabolic health, and cardiovascular prevention advancing through development.
For more information: www.newel.healthMedia contact: media@newel.health
Photo - https://mma.prnewswire.com/media/2704411/AMI_Magazine_pic.jpgLogo - https://mma.prnewswire.com/media/2704412/Newel_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/amicomed-by-newel-health-obtains-eu-mdr-certification-as-a-digital-medical-device-for-hypertension-management-302474795.html
Erreur lors de la récupération des données
Connectez-vous pour accéder à votre portefeuille
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025
BAAR, Switzerland, June 12, 2025--(BUSINESS WIRE)--Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow (United Kingdom) June 13-16. The company will present 25 posters and host two scientific symposia during which six world-leading experts will share their insight on respiratory and food allergy: "Breath of change: redefining respiratory allergy care with remission in sight": with environmental change impacting respiratory allergies, a new approach to disease management is necessary. Clinical remission is emerging as a relevant treatment goal for Type 2 allergies and allergen immunotherapy (AIT) has the potential to cater to this approach. "Myth busting in peanut allergy: separating fact from fiction": misconceptions about food allergy management may influence treatment decisions, thus underscoring the vital role of patient-clinician communication. "We are enthusiastic to share how Stallergenes Greer is bolstering its impact in the field of respiratory and food allergy. Our research findings highlighted at the symposia, as well as through scientific posters and presentations, reflect our determination to deliver innovative allergen immunotherapy solutions that offer sustained benefits for patients worldwide," stated Dr Elena Rizova, Chief Medical Officer, Stallergenes Greer. "Our portfolio offers a broad range of proven treatment solutions designed to provide long-lasting relief for patients with allergies across a spectrum of conditions ranging from allergic rhinitis and asthma to food allergy." The presentation of the posters will showcase Stallergenes Greer's latest research efforts and reaffirm its commitment to advancing personalised allergy care for the benefit of patients and healthcare professionals. Topics include patient benefits with AIT and its potential for clinical remission, new data from the recent real-world study VORAN on 300 IR House Dust Mite (HDM) SLIT tablet, PDAH (defatted powder of Arachis Hypogaea L., semen [peanut]) allergen consistency compared to supermarket peanut products, and prevention of food-induced anaphylaxis in children, including toddlers. SYMPOSIA AND POSTERS COMPANY SPONSORED SYMPOSIUM (June 13, 13:30–14:30 – Room: Meeting Academy M1) "Breath of change: redefining respiratory allergy care with remission in sight" Chair: Prof. Adnan Custovic, United Kingdom - "Climate, pollution, and the escalating allergy burden: time for a treatment paradigm shift"Speaker: Prof. Guillaume Lezmi, France - "From symptom control to disease remission: a new vision for allergic asthma"Speaker: Prof. Oliver Pfaar, Germany - "Allergen immunotherapy: unlocking sustainable relief for allergic rhinitis"Speaker: Prof. Randolph Brehler, Germany COMPANY SPONSORED SYMPOSIUM (June 14, 14:30–15:00 – Room: Boisdale) "Myth busting in peanut allergy: separating fact from fiction" Speakers: Dr Aikaterini Anagnostou, United States of America, and Dr Pablo Rodríguez del Río, Spain POSTERS Among the topics covered by the 25 posters, specific findings will be presented and discussed in depth: Recent findings highlight the potential of Stallergenes Greer immunotherapies to provide sustained symptom relief and reduce reliance on corticosteroids even after treatment cessation, aligning with the concept of clinical remission on and off treatment. Evidence from VORAN, the first European real-world data generation study with 300 IR HDM SLIT tablet, supports the safety profile and effectiveness of this treatment in HDM-induced allergic rhinitis with or without controlled asthma in more than 700 adults and adolescents, with over 80% having improved their symptoms and sleep and almost 2/3 stopping nasal corticosteroid use. These findings are further supported by the PRACTIS study, where the benefits of SLIT-liquid met expectations in approximately 90% of patients with allergic rhino conjunctivitis and/or asthma. Furthermore, Stallergenes Greer recently conducted studies showing that its peanut allergy treatment, PDAH, is consistent and offers a positive risk-benefit ratio. Unlike common peanut products found in supermarkets, which can vary in protein and allergen levels, PDAH shows consistency across batches. The research also points to an opportunity to help children from 1 year, when their immune systems may be more adaptable. In clinical studies, the treatment helped reduce the risk of accidental allergic reactions and showed a solid safety record, especially in toddlers. ABOUT THE EAACI CONGRESS The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956. EAACI is dedicated to improving the health of people affected by allergic diseases. With more than 16,000 members from 125 countries and over 50 National Allergy Societies, EAACI is the primary source of expertise in Europe and worldwide for all aspects of allergy. ABOUT STALLERGENES GREER Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, visit View source version on Contacts Stallergenes Greer Communications Catherine KressTel: +33 (0)1 55 50 26 05Email: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
WebMD
10 hours ago
- WebMD
FDA Approves New 3-in-1 Combo Pill for High Blood Pressure
June 11, 2025 – The FDA has approved a new pill for adults with high blood pressure (hypertension) that combines three medicines in one. Available in one regular and two lower doses, it offers a convenient option for treating hypertension, which affects nearly half of the adults in the U.S. and raises their risk of stroke and heart failure. Sold as Widaplik, it is the first and only single pill to combine three previously FDA-approved drugs – telmisartan, amlodipine, and indapamide – offering a triple-action approach for people who would otherwise need multiple pills to manage their blood pressure. It works in three ways and is a safe, well-tolerated early treatment option. Hypertension happens when your blood pushes too hard against your blood vessels, making the heart work harder and increasing the risk of heart problems, strokes, and other complications. It contributes to about 460,000 deaths annually in the U.S. and often goes undetected due to a lack of symptoms. With 1 in 3 Americans unaware they have it and only 1 in 4 managing it well, there's an urgent need for simpler, more effective treatments. The approval was based on two large studies that showed using Widaplik helped lower blood pressure more than using just two medicines or a placebo, according to a news release from the company that makes it, George Medicines. People who took Widaplik didn't stop taking it more often because of side effects, which means it was generally easy for them to take. Another trial showed that Widaplik was better at reducing blood pressure compared to standard care, while remaining well-tolerated. George Medicines stated that a global trial is underway to find out if the combo treatment can help prevent strokes in people who have previously had an intracerebral hemorrhage (sudden bleeding in the brain), the most serious type of stroke. "Single-pill combination antihypertensive therapy has great potential to improve hypertension control in the US and worldwide. Most patients with hypertension need multiple therapies to achieve their blood pressure goals. The new dose options available with Widaplik offer a treatment regimen that could benefit a broad range of patients, including those just starting treatment," Paul Whelton, MD, Show Chwan chair of global public health at Tulane University in New Orleans and past president of the World Hypertension League, said in a statement. Widaplik is a medicine made of three drugs that work together to help lower blood pressure. Two of them, telmisartan and amlodipine, relax blood vessels so blood can flow more easily. The third, indapamide, helps your body get rid of extra water by making you pee more. Widaplik comes in three strengths: 10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg. Low blood pressure – which can make you feel faint or dizzy – was the most common side effect, the company said. Patients who pass out should stop taking the medication and consult their doctor.
Associated Press
18 hours ago
- Associated Press
Conavi Medical to Present at the Life Sciences Virtual Investor Forum June 12th
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) ('Conavi Medical' or the 'Company'), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that Thomas Looby, CEO, will present live at the Life Sciences Virtual Investor Forum hosted by on June 12th, 2025 DATE: June 12th TIME: 2:00 PM ET LINK: REGISTER HERE This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. Learn more about the event at . Recent Company Highlights Upsized $20 million CAD financing led by U.S. institutional investors is expected to support finalizing product development of the next-generation Novasight Hybrid system, submit for regulatory clearance and enable commercial launch New U.S. intracoronary imaging guidelines from the American College of Cardiology and recent peer-reviewed research strongly validate Novasight's unique value proposition U.S. FDA 510(k) submission remains on track for calendar Q3 2025 About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare. For more information, visit . About Virtual Investor Conferences® Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors. Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors. Forward-Looking Statements This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Conavi and its business, which may include, but are not limited to, statements with respect to the anticipated use of proceeds from the April 2025 public offering, Conavi's exposure to the U.S. investment community, the commercialization and development of the Novasight Hybrid System and the achievement and timeline of key milestones towards commercialization and development of the Novasight Hybrid System. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are 'forward-looking information or statements'. Often but not always, forward-looking information or statements can be identified by the use of words such as 'shall', 'intends', 'anticipate', 'believe', 'plan', 'expect', 'intend', 'estimate' 'anticipate' or any variations (including negative variations) of such words and phrases, or state that certain actions, events or results 'may', 'might', 'can', 'could', 'would' or 'will' be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. They are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, those listed in the 'Risk Factors' section of the short form prospectus dated April 15, 2025 and the joint information circular of the Company dated August 30, 2024 (both of which are on the Company's profile at ). Although Conavi has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Conavi does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. No regulatory authority has approved or disapproved the content of this press release. Neither the TSX Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Contacts: Conavi Medical Stefano Picone Chief Financial Officer [email protected] (416) 483-0100 Virtual Investor Conferences John M. Viglotti SVP Corporate Services, Investor Access OTC Markets Group (212) 220-2221 [email protected]
